Regeneron revenue beats estimates on strong sales of Eylea, COVID therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Regeneron Pharma (REGN) PT Raised to $640 at Cowen
February 4, 2022 12:55 PM ESTCowen analyst Tyler Van Buren raised the price target on Regeneron Pharma (NASDAQ: REGN) to $640.00 (from $625.00) while maintaining a Market Perform rating following reuslts.
The analyst commented, "A strong commercial performance of the core business led to strong Q4 results. Understanding... More
